Tango Therapeutics, Inc. Shareholders' Equity
Tango Therapeutics, Inc. (TNGX) had Shareholders' Equity of $1.02 billion as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.02B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $391.51M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $346.18M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $160.03M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $1.02B 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $391.51M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $346.18M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $160.03M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $134.95M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $166.76M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $199.52M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $229.17M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $247.67M 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $264.45M 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $253.11M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $276.60M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $212.94M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $227.26M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $249.48M 10-K · filed 2026-03-05 | |
| 2022-09-30 | $273.07M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $298.70M 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $320.36M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $344.75M 10-K · filed 2025-02-27 | |
| 2021-09-30 | $365.41M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $54.89M 10-Q · filed 2022-11-10 | $5.00M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $57.89M 10-Q · filed 2022-11-10 | $5.00M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $38.60M 10-K · filed 2023-03-27 | $5.00M 10-K · filed 2021-03-31 |
| 2020-09-30 | $46.91M 10-Q · filed 2021-11-09 | $5.00M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $22.19M 10-Q · filed 2021-11-09 | $24.53K 10-Q · filed 2020-11-13 |
| 2020-03-31 | $417.00K 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $7.91M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |